pargyline has been researched along with Acute Confusional Senile Dementia in 28 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alzheimer's disease is a progressive brain disorder with characteristic symptoms and several pathological hallmarks." | 1.62 | 2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease. ( Andrys, R; Capek, J; Handl, J; Hrabinova, M; Janockova, J; Kobrlova, T; Korabecny, J; Marco-Contelles, JL; Mezeiova, E; Micankova, P; Muckova, L; Nepovimova, E; Pejchal, J; Rousar, T; Simunkova, M; Soukup, O; Valko, M, 2021) |
| "In the brains of patients with Alzheimer's disease, the enzymatic activities of butyrylcholinesterase (BChE) and monoamine oxidase B (MAO-B) are increased." | 1.46 | N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents. ( Brazzolotto, X; Brus, B; Colletier, JP; Coquelle, N; Gobec, S; Knez, D; Kos, J; Košak, U; Nachon, F; Pišlar, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (10.71) | 29.6817 |
| 2010's | 19 (67.86) | 24.3611 |
| 2020's | 6 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Gökhan-Kelekçi, N | 1 |
| Yabanoğlu, S | 1 |
| Küpeli, E | 1 |
| Salgin, U | 1 |
| Ozgen, O | 1 |
| Uçar, G | 1 |
| Yeşilada, E | 1 |
| Kendi, E | 1 |
| Yeşilada, A | 1 |
| Bilgin, AA | 1 |
| Lu, C | 1 |
| Zhou, Q | 1 |
| Yan, J | 1 |
| Du, Z | 1 |
| Huang, L | 4 |
| Li, X | 5 |
| Sun, Y | 1 |
| Chen, J | 2 |
| Chen, X | 1 |
| Huang, M | 1 |
| Xie, SS | 5 |
| Jiang, N | 4 |
| Lan, JS | 4 |
| Kong, LY | 5 |
| Wang, XB | 3 |
| Wang, X | 2 |
| Yu, W | 1 |
| Wang, KD | 1 |
| Li, ZR | 1 |
| Xie, S | 1 |
| Su, T | 1 |
| Wang, Y | 1 |
| Wang, Z | 1 |
| Wang, ZM | 1 |
| Li, F | 2 |
| Wu, JJ | 2 |
| Wang, J | 2 |
| Košak, U | 1 |
| Knez, D | 1 |
| Coquelle, N | 1 |
| Brus, B | 1 |
| Pišlar, A | 1 |
| Nachon, F | 1 |
| Brazzolotto, X | 1 |
| Kos, J | 1 |
| Colletier, JP | 1 |
| Gobec, S | 1 |
| Yang, HL | 2 |
| Cai, P | 2 |
| Liu, QH | 2 |
| Yang, XL | 2 |
| Ding, Y | 1 |
| Liu, Y | 1 |
| Kang, P | 1 |
| Hou, JW | 1 |
| Zhang, XY | 1 |
| Zhang, T | 1 |
| Fang, SQ | 1 |
| Tang, YW | 1 |
| Wang, C | 1 |
| Xu, YX | 1 |
| Wang, H | 1 |
| Li, XK | 1 |
| Dong, SN | 1 |
| Liu, WW | 1 |
| Gong, Q | 1 |
| Wang, TD | 1 |
| Tang, Y | 1 |
| Zhu, J | 2 |
| Li, J | 2 |
| Zhang, HY | 1 |
| Mao, F | 2 |
| Kumar, B | 1 |
| Kumar, V | 2 |
| Prashar, V | 1 |
| Saini, S | 1 |
| Dwivedi, AR | 1 |
| Bajaj, B | 1 |
| Mehta, D | 1 |
| Parkash, J | 1 |
| Zhang, C | 3 |
| Yang, K | 1 |
| Yu, S | 1 |
| Su, J | 1 |
| Yuan, S | 1 |
| Han, J | 1 |
| Chen, Y | 1 |
| Gu, J | 2 |
| Zhou, T | 3 |
| Bai, R | 4 |
| Xie, Y | 4 |
| Jiang, X | 3 |
| Guo, J | 3 |
| Lv, Y | 1 |
| Yao, C | 3 |
| Mi, Z | 1 |
| Shi, Y | 1 |
| Liu, J | 1 |
| Tang, C | 1 |
| Pang, C | 1 |
| Li, Q | 1 |
| Qin, Y | 1 |
| Nong, X | 1 |
| Zhang, Z | 1 |
| Cheng, M | 1 |
| Tang, W | 1 |
| Liang, N | 1 |
| Mezeiova, E | 1 |
| Janockova, J | 1 |
| Andrys, R | 1 |
| Soukup, O | 1 |
| Kobrlova, T | 1 |
| Muckova, L | 1 |
| Pejchal, J | 1 |
| Simunkova, M | 1 |
| Handl, J | 1 |
| Micankova, P | 1 |
| Capek, J | 1 |
| Rousar, T | 1 |
| Hrabinova, M | 1 |
| Nepovimova, E | 1 |
| Marco-Contelles, JL | 1 |
| Valko, M | 1 |
| Korabecny, J | 1 |
| Zhao, R | 1 |
| Zhong, Z | 2 |
| Ge, J | 2 |
| Ye, XY | 1 |
| Liu, Z | 1 |
| Xie, T | 1 |
| do Carmo Carreiras, M | 1 |
| Ismaili, L | 1 |
| Marco-Contelles, J | 4 |
| Zhang, Y | 1 |
| Zhang, J | 1 |
| Wang, L | 1 |
| Esteban, G | 1 |
| Ojima, M | 1 |
| Bautista-Aguilera, OM | 1 |
| Inokuchi, T | 1 |
| Moraleda, I | 2 |
| Iriepa, I | 2 |
| Samadi, A | 2 |
| Youdim, MB | 3 |
| Romero, A | 2 |
| Soriano, E | 1 |
| Herrero, R | 1 |
| Fernández Fernández, AP | 1 |
| Unzeta, M | 3 |
| Wei, H | 1 |
| Ramos, E | 1 |
| Del Pino, J | 1 |
| Bar-Am, O | 1 |
| Amit, T | 1 |
| Weinreb, O | 1 |
| Mandel, S | 1 |
| de los Ríos, C | 1 |
| Bolea, I | 2 |
| Chioua, M | 1 |
| Bartolini, M | 1 |
| Andrisano, V | 1 |
| Gálvez, E | 1 |
| Valderas, C | 1 |
| Gella, A | 1 |
| Sterling, J | 1 |
| Herzig, Y | 1 |
| Goren, T | 1 |
| Finkelstein, N | 1 |
| Lerner, D | 1 |
| Goldenberg, W | 1 |
| Miskolczi, I | 1 |
| Molnar, S | 1 |
| Rantal, F | 1 |
| Tamas, T | 1 |
| Toth, G | 1 |
| Zagyva, A | 1 |
| Zekany, A | 1 |
| Finberg, J | 1 |
| Lavian, G | 1 |
| Gross, A | 1 |
| Friedman, R | 1 |
| Razin, M | 1 |
| Huang, W | 1 |
| Krais, B | 1 |
| Chorev, M | 1 |
| Weinstock, M | 1 |
| Dell'Antone, P | 1 |
| IbnLkayat, M | 1 |
| Drago, D | 1 |
| Zatta, P | 1 |
3 reviews available for pargyline and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Propargylamine-derived multi-target directed ligands for Alzheimer's disease therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Cholinesterases; Humans; L | 2020 |
Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Humans; Mitogen-Activated Protein Kinases; Pargyl | 2010 |
Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Humans; Ligands; Monoam | 2013 |
25 other studies available for pargyline and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics.
Topics: Alzheimer Disease; Analgesics; Animals; Anti-Inflammatory Agents; Edema; Hindlimb; Hydrogen Bonding; | 2007 |
A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Dose-Response Relationship, Drug; En | 2013 |
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Electro | 2013 |
Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Blood-Brain Barrier; Cell Line, Tu | 2015 |
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzopyrans; Blood-Brain Barrier; Brain; Cell Survival; Cel | 2015 |
Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Cations, Divalent; Cell Membrane Permeabilit | 2015 |
Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line, Tumor; Cholinesterase Inhibitors; Chol | 2016 |
N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Butyrylcholinesterase; Cell Death; Cell Line; Cholinestera | 2017 |
Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Coumarins; Dose-Response Relations | 2017 |
Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; | 2017 |
Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Dose-Response Relationship, Drug; | 2017 |
Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2018 |
Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase.
Topics: Acetylcholinesterase; Alkynes; Alzheimer Disease; Catalytic Domain; Cell Line, Tumor; Cholinesterase | 2019 |
Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cell Line, Tumor; Cell Survival; Coumarins; Dose-Response Relationship, | 2019 |
Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Behavior, Animal; Binding Sites; Ce | 2020 |
Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Cell Survival; Clorgyline; Dose | 2020 |
2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Drug Design; Humans; Naphthoquinones; Structure-Activity Relationship | 2021 |
HDAC1/MAO-B dual inhibitors against Alzheimer's disease: Design, synthesis and biological evaluation of N-propargylamine-hydroxamic acid/o-aminobenzamide hybrids.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Drug Design; Hydroxamic Acids; Mice; Mice, In | 2022 |
N-Propargylamine-hydroxypyridinone hybrids as multitarget agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Disease Models, Animal; Drug Design; Drug Stability | 2021 |
Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Chelating Agents; Cholinesterase Inhibitors; Donep | 2014 |
Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cell Survival; Cholinesterase Inhibitors; Dose-Response Rel | 2015 |
Upregulation of Antioxidant Enzymes by ASS234, a Multitarget Directed Propargylamine for Alzheimer's Disease Therapy.
Topics: Alzheimer Disease; Animals; Catalase; Cholinesterase Inhibitors; Humans; Indoles; Pargyline; Piperid | 2016 |
Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chem | 2012 |
Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Butyrylcholinesterase; Carbamates; | 2002 |
Acidic vesicles of the endo-exocytic pathways as targets for some anti-monoamine oxidase drugs.
Topics: Acid-Base Equilibrium; Acids; Alzheimer Disease; Amantadine; Animals; Brain; Brain Chemistry; Brain | 2009 |